Recent Quotes
My Watchlist
Indicators
Local Stocks
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exact Sciences Cor (NQ: EXAS )

50.16 -1.17 (-2.28%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,194,284
Open 50.61
Bid (Size) 49.25 (10)
Ask (Size) 50.16 (5)
Prev. Close 51.33
Today's Range 48.02 - 51.00
52wk Range 40.62 - 79.62
Shares Outstanding 171,948,769
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?
The company reported lighter-than-expected third-quarter sales due to issues with physician order rates. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga

Performance

YTD
-32.00%
-32.00%
1 Month
-29.24%
-29.24%
3 Month
-14.72%
-14.72%
6 Month
-7.11%
-7.11%
1 Year
-15.37%
-15.37%

More News

Read More
Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
Via Benzinga
Exact Sciences Posts Downbeat Results, Joins Super Micro Computer, Honda Motor And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Will EXACT SCIENCES CORP breakout?
Via Chartmill
Deep Dive Into Exact Sciences Stock: Analyst Perspectives (7 Ratings)
Via Benzinga
Why Tesla Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Exact Sciences (EXAS) Q3 2024 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Exact Sciences Stock Plummets After Worse-Than-Expected Q3 Results, FY24 Guidance Below Estimates
Via Benzinga
Exact Sciences Announces Third-Quarter 2024 Results
From Exact Sciences Corp.
Via Business Wire
(EXAS) - Analyzing Exact Sciences's Short Interest
Via Benzinga
Analyst Ratings For Exact Sciences
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Exact Sciences
Via Benzinga
Exact Sciences to Participate in November Investor Conference
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Presents Multiple Studies at ACG 2024 Demonstrating Leadership in Noninvasive Colorectal Cancer Screening and Patient Engagement
From Exact Sciences Corp.
Via Business Wire
Can This Beaten-Down Cathie Wood Stock Bounce Back?
Via The Motley Fool
Exact Sciences Schedules Third Quarter 2024 Earnings Call
From Exact Sciences Corp.
Via Business Wire
FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test
Via Benzinga
Exposures Product Safety
Exact Sciences Stock Rises After FDA Signs Off On New Cologuard
Via Investor's Business Daily
Exposures Product Safety
FDA Approves Exact Sciences’ Cologuard Plus Test, Setting a New Benchmark in Non-Invasive Colorectal Cancer Screening
From Exact Sciences Corp.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Exact Sciences Presents Data Demonstrating Advancement in Blood-based Colorectal Cancer Screening at ESMO 2024
From Exact Sciences Corp.
Via Business Wire
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
Via Benzinga
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.